Enrolling Clinical Studies
Enrolling Clinical Trials
Gastroenterology
Non-Alcoholic Steatohepatitis (NASH)
A Phase 3 study sponsored by Madrigal Pharmaceuticals to evaluate the effect of a new investigational oral medication on liver-related outcomes in patients with well-compensated Non-alcoholic Steatohepatitis (NASH).
You may qualify for this no-cost clinical trial if you:
- Are 18+ years of age
- Have been diagnosed with NASH (with stage 4 fibrosis score)
Infectious Disease
Functional Cure Study for People Living With HIV
A Phase II study sponsored by Abbvie to evaluate the safety and tolerability of two infused investigational medications. A combination of these study drugs is hypothesized to boost HIV-specific T cell response, leading to immunosurveillance for ART-free viral control.
You may qualify for this no-cost clinical trial if you:
- 18 to 70 years of age, inclusive
- in good overall health
- on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 8 weeks prior to screening
- Current ART regimen cannot include NNRTI.
Pulmonology
Chronic Obstructive Pulmonary Disease (COPD)
COPD is a chronic inflammatory lung disease which causes obstructed airflow from the lungs. COPD is most often caused from a smoking history and may increase your risk of heart disease and lung cancer.
Symptoms include:
- Breathing difficulty/Shortness of breath
- Coughing/Wheezing
- Chest tightness
- Sputum (mucus) production
You may qualify for this no-cost clinical trial if you:
- Are 40 - 85 years of age
- Have moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
- History of 2 moderate or 1 severe COPD exacerbations in the previous 12 months
- Use of triple (ICS/LABA/LAMA) therapy for COPD
Qualified volunteers may receive at no cost:
- Study medication
- Study-related care
- Reimbursement for your travel
Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this research study from Sanofi is to evaluate the Safety and Efficacy of an investigational study drug in subjects with moderate-to-severe COPD.
Symptoms include:
- Breathing difficulty/Shortness of breath
- Coughing/Wheezing
- Chest tightness
- Sputum (mucus) production
You may qualify for this no-cost clinical trial if you:
- Are 40 - 85 years of age
- Have moderate to very severe COPD
- Have a history of 2 moderate or 1 severe COPD exacerbations in the prior 12 months
Qualified volunteers may receive at no cost:
- Study medication
- Study-related care
- Reimbursement for your travel
Idiopathic Pulmonary Fibrosis (IPF)
Sponsored by United Therapeutics Corp, the purpose of this Phase 3 study is to evaluate safety and efficacy of an inhaled investigational study medication for people with IPF.is a a chronic, progressive, irreversible, and usually lethal lung disease of unknown cause that occurs mostly in elderly adults.
Symptoms include:
- Worsening cough & shortness of breath
- Fatigue
- Unexplained weight loss
- Muscle & joint pain
You may qualify for this no-cost clinical trial if you:
- Are 40 - 85 years of age.
- Have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF) within the last 3 years
Lung Cancer Screening Blood Sample Collection Study
The purpose of this research study from Roche Molecular Systems is to collect blood samples and medical information to help in the development of a blood test that can screen for many cancers from a single blood draw
Health insurance and doctor referrals are not required to participate in the clinical trials & clinical studies.
Upcoming Clinical Trials
Non-Alcoholic Steatohepatitis (NASH)
The purpose of this research study from Akero is to evaluate the Safety and Efficacy of an investigational study drug in subjects with compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH).
Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this research study from Pliant Therapeutics is to evaluate the efficacy and safety of an investigational oral study drug for the treatment of IPF.